The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.
Since President Donald Trump began his emphatic push to reduce drug prices, a looming question has been how low he could bring down the price
Novo Nordisk has once again upped its bid for Metsera, according to sources familiar with the matter, in an effort to beat out a raised
Plus, news about Cullinan, 4DMT, Axsome, AstraZeneca, Noema, UroGen Pharma, Halozyme and Benitec: ↩️ Dyne delays myotonic dystrophy plans again: Dyne said it now expects
Vera Therapeutics built its case for a rare kidney disease drug Thursday morning, revealing a fuller Phase 3 dataset after toplining the results earlier this
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
UPS has acquired US-based supply chain management firm Andlauer Healthcare for …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844